CCL5 and neoplasm: Using an adenovirus (AdV5) designed to target tumor cells and induce IL-12 expression in a B16-HER2 orthotopic mouse tumor model, the authors observed that IL-12 anti-tumor efficacy was dependent on CCL5 production by a population of CD49+-tissue resident NK cells [221].